Mitotic recombination: A genotoxic effect of the antidepressant citalopram in Aspergillus nidulans

Experimental Biology and Medicine

Volumn 235, Issue 10, 2010, Pages 1257-1262

  Franco, Claudinéia C S ^a   Castro Prado, Juliana ^a   Rosada, Lúcia J ^a   Sant'Anna, Juliane R ^a   Castro Prado, Marialba A A ^a  

^a STATE UNIVERSITY OF MARINGÁ   (Brazil)

Author keywords

Cancer patients; Citalopram; Second malignancy; Somatic recombination; Tumor promoters

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; CARCINOGEN; GENETIC MARKER; MUTAGENIC AGENT;

ARTICLE; ASPERGILLUS NIDULANS; CONTROLLED STUDY; DIPLOIDY; DNA STRAND BREAKAGE; DNA SYNTHESIS INHIBITION; FUNGAL STRAIN; GENETIC MARKER; GENOTOXICITY; HOMOZYGOSITY; MITOTIC RECOMBINATION; NONHUMAN; COMPLICATION; CROSSING OVER; CYTOLOGY; DEPRESSIVE DISORDER; DNA DAMAGE; DNA REPAIR; DRUG EFFECTS; FUNGAL GENE; GENETIC RECOMBINATION; GENETICS; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MITOSIS; NEOPLASMS; TOXICITY;

EMERICELLA NIDULANS; FUNGI;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ASPERGILLUS NIDULANS; CARCINOGENS; CITALOPRAM; CROSSING OVER, GENETIC; DEPRESSIVE DISORDER; DIPLOIDY; DNA DAMAGE; DNA REPAIR; GENES, FUNGAL; GENETIC MARKERS; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MITOSIS; MUTAGENS; NEOPLASMS; RECOMBINATION, GENETIC;

EID: 77957825028     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1258/ebm.2010.010159     Document Type: Article

References (49)

1. DeJong M, Fombonne E. Citalopram to treat depression in pediatric oncology. J Child Adolesc Psychopharmacol 2007;17:371-7 (Pubitemid 47067961)
2. Ohayon MM, Lader MH. Use of psychotropic medication in the general population of France, Germany, Italy, and the United Kingdom. J Clin Psychiatry 2002;63:817-25
3. Stafford RS, MacDolald EA, Finkelstein SN. National patters of medication treatment for depression 1987 to 2001. Prim Care Companion J Clin Psychiatry 2001;3:232-5
4. Joubert AF, Sánchez C, Larsen F. Citalopram. Hum Psychopharmacol 2000;15:439-51
5. Bozkurt G, Abay E, Ates I, Karabogaz G, Ture M, Savran FO, Palanduz S, Temocin K, Algunes C. Clastogenicity of selective serotonin-reuptake inhibitors. Mutat Res 2004;558:137-44
6. Hilakivi-Clarke L, Wright A, Lippman ME. Neonatal antidepressant treatment promotes DMBA-induced mammary tumor growth. Proc Am Assoc Cancer Res 1993;34:184
7. Brandes LJ, Arron RJ, Bogdanovic RP, Tong J, Zaborniak CLF, Hogg GR, Warrington RC, Fang W, Labella FS. Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses. Cancer Res 1992;52:3796-800
8. Moorman PG, Grubber JM, Millikan RC, Newman B. Antidepressant medications and their association with invasive breast cancer and carcinoma in situ of the breast. Epidemiology 2003;14:307-14
9. Steingart A, Cotterchio M, Kreiger N, Sloan M. Antidepressant medication use and breast cancer risk: a case-control study. Int J Epidemiol 2003;32:961-6
10. Kelly JP, Rosenberg L, Palmer JR, Rao RS, Strom BL, Stolley PD, Zauber AG, Shapiro S. Risk of breast cancer according to use of antidepressants, phenothiazines, and antihistamines. Am J Epidemiol 1999;150:861-8
11. Chien C, Li CI, Heckbert SR, Malone KE, Boudreau DM, Daling JR. Antidepressant use and breast cancer risk. Breast Cancer Res Treat 2006;95:131-40
12. Wang PS, Walker AM, Tsuang MT, Orav EJ, Levin R, Avorn J. Antidepressant use and risk of breast cancer: a non association. J Clin Epidemiol 2001;54:728-34 (Pubitemid 32600045)
13. Van der Heijden MS, Yeo CJ, Hruban RH, Kern SE. Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res 2003;63:2585-8
14. Steingart AB, Cotterchio M. Do antidepressants cause, promote, or inhibit cancers? J Clin Epidemiol 1995;48:1407-12
15. Tanaka K, Mansoor AM, Shigeta C, Oguma N, Kamada N. Loss of heterozygosity at D3S2 locus of short arm of chromosome 3 in chronic myelogenous leukemia. Cancer Genet Cytogenet 1992;61:42-5
16. Howarth K, Ranta S, Winter E, Teixeira A, Schaschl H, Harvey JJ, Rowan A, Jones A, Spain S, Clark S, Guenther T, Stewart A, Silver A, Tomlinson I. A mitotic recombination map proximal to the APC locus on chromosome 5q and assessment of influences on colorectal cancer risk. BMC Med Genet 2009;10:1-11
17. Miyaki M, Tanaka K, Kikuchi-Yanoshita R, Muraoka M, Konishi M. Familial polyposis: recent advances. Crit Rev Oncol Hematol 1995;19:1-31
18. Payne M, Hickson ID. Genomic instability and cancer: lessons from analysis of Bloom's syndrome. Biochem Soc Trans 2009;37:553-9
19. Luo G, Santoro IM, McDaniel LD, Nishijima I, Mills M, Youssoufian H, Vogel H, Schultz RA, Bradley A. Cancer predisposition caused by elevated mitotic recombination in Bloom mice. Nat Genet 2000;26:424-9
20. Chaganti RS, Schonberg S, German J. A manyfold increase in sister chromatid exchanges in Bloom's syndrome lymphocytes. Proc Natl Acad Sci USA 1974;71:4508-12
21. Bergen GG, Morris NR. Kinetics of the nuclear division cycle of Aspergillus nidulans. J Bacteriol 1983;156:155-60
22. Castro-Prado J, Franco CCS, Santanna JR, Miyamoto CT, Castro-Prado MAA. Recombinogenic activity of fluoxetine in Aspergillus nidulans. Drug Chem Toxicol 2009;32:338-43
23. Sant'Anna JR, Miyamoto CT, Franco CCS, Miguel OG, Cunico MM, Côcco LC, Yamamoto CI, Júnior CC, Castro-Prado MAA. Genotoxicity of Achillea millefolium essential oil in diploid cells of Aspergillus nidulans. Phytother Res 2009;23:231-5
24. Miyamoto CT, Sant'Anna JR, Franco CCS, Castro-Prado MAA. Genotoxicity (mitotic recombination) of the cancer chemotherapeutic agents cisplatin and cytosine arabinoside in Aspergillus nidulans. Food Chem Toxicol 2007;45:1091-5
25. Arnaudeau C, Tenorio Miranda E, Jensen D, Helleday T. Inhibition of DNA synthesis is a potent mechanism by which cytostatic drugs induce homologous recombination in mammalian cells. Mutat Res 2000;461:221-8
26. Dhawan A, Kayani MA, Parry JM, Parry E, Anderson D. Aneugenic and clastogenic effects of doxorrobicin in human lymphocytes. Mutagenesis 2003;18:487-90 (Pubitemid 37461548)
27. Helen KDB, Subramanyam S. Genotoxic evaluation of ara-c by multiple parameters. Mutat Res 1991;263:185-96
28. Becker TCA, Castro-Prado MAA. Parameiosis in Aspergillus nidulans in response to doxorubicin. Folia Microbiol 2004;49:699-704
29. Roper JA. Production of heterozygous diploids in filamentous fungi. Experientia 1952;8:14-15
30. Serafein A, Holder MJ, Grafton G, Chamba A, Drayson MT, Luong QT, Bunce CM, Gregory CD, Barnes NM, Gordon J. Selective serotonin inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells. Blood 2003;101:3212-19 (Pubitemid 36858017)
31. Kaneshima EN, Castro-Prado MAA. Benznidazole-induced genotoxicity in diploid cells of Aspergillus nidulans. Mem Inst Oswaldo Cruz 2005;100:325-9
32. Santos SJ, Takahashi CS, Natarajan AT. Cytogenetic effects of the antichagasic benznidazole on human cells in vitro. Mutat Res 1994;320:305-14
33. Willers H, McCarthy EE, Wu B. Dissociation of p53-mediated suppression of homologous recombination from G1/S cell cycle checkpoint control. Oncogene 2000;19:632-9 (Pubitemid 30102914)
34. Szewczuk W, Skomra D, Cybulski M, dka-Rabaniuk DP, Filip A, Jóźwik M, Olcha P, Roessner A, Semczuk A. Allelic loss at TP53 in metastatic human endometrial carcinomas. Clin Exp Metastasis 2009;26:789-96
35. Yang Q, Zhang R, Wang XW, Spillare EA, Linke SP, Subramanians D, Griffith JD, Li JL, Hickson ID, Shen JC, Loeb LA, Mazur SJ, Appella E, Brosh RM, Karmakar P, Bohr VA, Harris CC. The processing of Holliday junctions by BLM and WRN helicases is regulated by p53. J Biol Chem 2002;277:31980-7
36. Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 2000;77:81-137 (Pubitemid 29439303)
37. Lasko D, Cavenee W, Nordenskjold M. Loss of constitutional heterozygosity in human cancer. Ann Rev Genet 1991;25:281-314 (Pubitemid 21903723)
38. Schild D, Wiese C. Overexpression of RAD51 suppresses recombination defects: a possible mechanism to reverse genomic instability. Nucleic Acids Res 2010;38:1061-70
39. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002;108:171-82
40. Bishop AJR, Schiestl RH. Homologous recombination and its role in carcinogenesis. J Biomed Biotechnol 2002;2:75-85 (Pubitemid 44204493)
41. Rousseau-Merck MF, Versteege I, Legrand I, Couturier J, Mairal A, Delattre O, Aurias A. hSNF5/INI1 inactivation is mainly associated with homozygous deletions and mitotic recombinations in rhabdoid tumors. Cancer Res 1999;59:3152-6 (Pubitemid 29316015)
42. Grundy P, Wilson B, Telzerow P, Zhou W, Paterson MC. Uniparental disomy occurs infrequently in Wilms' tumor patients. Am J Hum Genet 1994;54:282-9 (Pubitemid 24046340)
43. Zhu X, Dunn JM, Goddard AD, Squire JA, Becker A, Phillips RA, Gallie BL. Mechanisms of loss of heterozygosity in retinoblastoma. Cytogenet Cell Genet 1992;59:248-52
44. Roscoe JA, Morrow GR, Hickok JT, Mustian KM, Griggs JJ, Mattrson SE, Bushunow P, Qazi R, Smith B. Effect of paroxetine hydrochloride (Paxil®) on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat 2005;89:243-9 (Pubitemid 43293071)
45. Fisch M. Treatment of depression and cancer. J Natl Cancer Inst Monogr 2004;32:105-11
46. Fisch MJ, Loehrer PJ, Kristeller J. Fluoxetina versus placebo in advanced cancer outpatients: a double-blinded trial of the hoosier oncology group. J Clin Oncol 2003;21:1937-43 (Pubitemid 46606381)
47. Portteus A, Ahmad N, Tobey D, Leavery PL. The prevalence and use of antidepressant medication in pediatric cancer patients. J Child Adolesc Psychopharmacol 2006;16:467-73 (Pubitemid 44681466)
48. L. Biochem Pharmacol 1999;57:1199-208
49. Wernli KJ, Hampton JM, Trentham-Dietz A, Newcomb A. Antidepressant medication use and breast cancer risk. Pharmacoepidemiol Drug Saf 2009;18:284-90